Challenges for Drug Repurposing in the COVID-19 Pandemic Era
The coronavirus disease (COVID-19) pandemic has affected an estimated 16 million persons and caused 0.6 million deaths worldwide by September 2020. The pandemic has led to a rush to repurpose existing drugs, although the underlying evidence base is of variable quality. The improving knowledge of the...
Saved in:
Main Authors: | Janet Sultana (Author), Salvatore Crisafulli (Author), Flic Gabbay (Author), Elizabeth Lynn (Author), Saad Shakir (Author), Gianluca Trifirò (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2020-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A New Era of Pharmacovigilance: Future Challenges and Opportunities
by: Gianluca Trifirò, et al.
Published: (2022) -
Digital Therapeutics in Perspective: From Regulatory Challenges to Post-Marketing Surveillance
by: Salvatore Crisafulli, et al.
Published: (2022) -
What Is the Difference Between Observed Association and Causal Association, Signals and Evidence? Examples Related to COVID-19
by: Vicki Osborne, et al.
Published: (2021) -
The Regulatory Challenges for Drug Repurposing During the Covid-19 Pandemic: The Italian Experience
by: Lucia Gozzo, et al.
Published: (2020) -
Challenges in Repurposing Drugs in COVID-19 Pandemic. Debating on Potential New Refinements
by: Giorgio Frega, et al.
Published: (2020)